Understanding how siRNA stimulates this undesirable immune activity, how to test for it, and how to design siRNA drugs to avoid it are critical topics explored in a new review article.

Understanding how siRNA stimulates this undesirable immune activity, how to test for it, and how to design siRNA drugs to avoid it are critical topics explored in a timely review article published ...

Small interfering RNA (siRNA) has shown tremendous potential for treating human diseases in the past decades. siRNA can selectively silence a pathological pathway through the targeting and ...

Exosomal siMecA (an siRNA designed to target the mecA gene) can downregulate the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance ...

The critical factors that affect siRNA function and specificity (off-targeting), such as siRNA design, chemical modifications and concentration, will be covered in detail. The practical application of ...

“Design algorithms use bioinformatics to minimize unintentional gene targeting but this should be confirmed experimentally by the end user.” Plus, siRNA degrades over time.

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

LONDON, April 21 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the Company and AstraZeneca (LSE: AZN) have agreed to a one-year extension of their ...

ETX‑312 is a GalOmic GalNAc-conjugated small-interfering RNA (GalNAc-siRNA) therapeutic candidate in development to be a safe and effective treatment for metabolic dysfunction-associated ...

This is an introduction to the biological mechanism of RNA interference (RNAi) and experimental application of short, interfering RNA (siRNA). The key steps of the endogenous RNAi pathway will be ...